The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...

HIMS rebounds on GLP-1 growth and rising earnings estimates, while DXC slumps amid falling sales and eroding investor ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Minister Sharanprakash Patil ensures quality education at Haveri Institute of Medical Sciences, addressing issues and overseeing renovations.

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 13 Best Booming Stocks to Buy Now. On July 9, the digital health and ...